A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

A Nigerian researcher, Dr Jerry Adeyemo, has identified alternative therapies that could help in the treatment of prostate ...

The University of Arkansas for Medical Sciences (UAMS) recently became the first provider in Arkansas of NanoKnife technology ...

Q4 2024 Earnings Call Transcript March 27, 2025 EDAP TMS S.A. beats earnings expectations. Reported EPS is $-0.05, ...

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

Focal One Procedures Growth (2024): Approximately ... is making significant progress in expanding Focal One robotic HIFU beyond prostate cancer, with clinical trials for pancreatic tumors and ...

The study evaluated HIFU versus radical prostatectomy (RP) as a first line treatment of localized prostate cancer. The paper is entitled ... released the final payment rules for 2025. The HIFU ...

The HIFU procedure continues to be supported with favorable reimbursement ... by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the ...

At Loyola Medicine, we’re working to ease those fears with an innovative, incision-free treatment option called High-Intensity Focused Ultrasound (HIFU) and a comprehensive survivorship program.

Good day, everyone, and welcome to today's EDAP TMS Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. Later, you will have the ...

AUSTIN, Texas, March 27, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the fourth quarter and full ...